Genocea Biosciences, Inc.
GNCAQ
$0.00
$0.000.00%
OTC PK
| 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 262.25% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 262.25% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 262.25% | -- | -- |
| SG&A Expenses | -1.96% | -19.37% | 6.59% | 15.89% | 8.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.15% | 23.86% | 19.34% | 20.54% | -7.13% |
| Operating Income | -26.98% | -23.86% | -9.10% | -30.33% | 7.13% |
| Income Before Tax | -33.34% | 11.38% | 20.48% | 61.92% | 6.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.34% | 11.38% | 20.48% | 61.92% | 6.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.34% | 11.38% | 20.48% | 61.92% | 6.77% |
| EBIT | -26.98% | -23.86% | -9.10% | -30.33% | 7.13% |
| EBITDA | -27.67% | -23.45% | -8.54% | -30.27% | 8.08% |
| EPS Basic | -24.08% | 18.67% | 36.78% | 83.68% | 60.35% |
| Normalized Basic EPS | -24.03% | 11.87% | 36.84% | 83.69% | 60.35% |
| EPS Diluted | -24.08% | 18.67% | 79.73% | 47.41% | 60.63% |
| Normalized Diluted EPS | -24.03% | 11.87% | 30.47% | 84.18% | 60.35% |
| Average Basic Shares Outstanding | 7.50% | 8.94% | 25.80% | 133.24% | 135.09% |
| Average Diluted Shares Outstanding | 7.50% | 8.94% | 14.19% | 140.90% | 135.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |